The Combination of Insulin-Like Growth Factor I and Insulin-Like Growth Factor-Binding Protein-3 Reduces Insulin Requirements in Insulin-Dependent Type 1 Diabetes: Evidence for in Vivo Biological Activity1
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Insulin-like growth factor-I (IGF-I) enhances insulin action in normal subjects and in patients with both type 1 and 2 diabetes; however, its administration is associated with significant side effects in a high percentage of patients. The coadministration of IGF binding protein-3 (IGFBP-3, the predominant IGF binding protein in serum) with IGF-I limits IGF-I inducible side effects, but it does not attenuate the ability of IGF-I to enhance protein synthesis and bone accretion; therefore, we determined whether IGF-I/IGFBP-3 would retain biological activity in type 1 DM and limit side effects associated with free IGF-I administration. Twelve patients received recombinant human IGF-I plus IGFBP-3 (2 mg/kg-day) by continuous sc infusion for 2 weeks. Each subject served as his own control; and, during a paired 2-week period, each received a placebo infusion. The order of the treatments was randomized. Subjects were placed on a constant caloric intake but were allowed to adjust insulin doses to maintain appropriate levels of glycemic control. Subjects measured blood glucose four times per day at home and kept a log of their insulin use. Frequent sampling for glucose, insulin, and GH was conducted during four inpatient study periods, one at the beginning and one at the end of each 2-week study interval. During IGF-I/IGFBP-3, insulin doses were reduced by 49%, and mean serum glucose was reduced by 23%. Free insulin levels obtained during frequent sampling in hospital fell 47% on IGF-I/IGFBP-3, compared with control, but showed no change with placebo. Concomitant glucose measurements did not differ in the two treatment groups. There was no change in body weight. Fructosamine levels decreased by 12%, but this was not significant (P < 0.1). Fasting triglyceride was unchanged, but cholesterol declined from 170 +/- 24 to 149 +/- 31 mg/dL (P < 0.05). IGFBP-2 (an IGF-I-dependent responsive variable) rose from 141 +/- 56 to 251 +/- 98 ng/mL (P < 0.01) on IGF-I/IGFBP-3. To analyze the mechanism by which IGF-I/IGFBP-3 might reduce insulin requirements, the change in serum GH was quantified. Mean GH levels were reduced by 72%, from 2.48 to 0.55 ng/mL (P < 0.001). An equal number (40%) of drug- and placebo-treated subjects had minor hypoglycemic episodes at home that required adjustment of insulin doses. No episode was classified as severe. In contrast to previous studies with free IGF-I, there were no cases of edema, headache, jaw pain, retinal edema, or Bell's palsy. No subject withdrew because of drug complications. These findings indicate that IGF-I/IGFBP-3 is biologically active on carbohydrate metabolism, as measured by a decrease in insulin requirements in patients with type 1 diabetes. Further studies will be required to determine the long-term safety and efficacy of this combination in patients with insulin resistance and diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moses, A. C., Young, S. C., Morrow, L. A., O'Brien, M., & Clemmons, D. R. (1996) · Diabetes · doi:10.2337/diab.45.1.91 · Cited by 291 · cited 3×
“However, we did note a 1.8-fold increase in IGFBP-2 that was substantially less than the 3.2-fold increase noted previously with administration of free IGF-I ( 6 ).”
BackgroundResultInfluentialSelf-citationThrailkill, K. M., Quattrin, T., Baker, L., Kuntze, J. E., Compton, P. G., & Martha, P. M. (1999) · Diabetes Care · doi:10.2337/diacare.22.4.585 · Cited by 88
Cited by
Effects of Growth Hormone on Glucose, Lipid, and Protein Metabolism in Human Subjects
Møller, N., & Jørgensen, J. O. L. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0027 · Cited by 1,039
Sandhu, M. S. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.13.972 · Cited by 496
The Role of Liver-Derived Insulin-Like Growth Factor-I
Ohlsson, C., Mohan, S., Sjögren, K., Tivesten, A., Isgaard, J., Isaksson, O., Jansson, J.-O., & Svensson, J. (2009) · Endocrine Reviews · doi:10.1210/er.2009-0010 · Cited by 453
Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1
LeRoith, D., & Yakar, S. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0427 · Cited by 344
“When rhIGF1 was administered to patients with type 1 diabetes over a 14-day period, there was a 50% reduction in insulin requirements and a decrease in blood glucose levels, which suggested an increase in insulin sensitivity”
MethodLiver-Specific igf-1 Gene Deletion Leads to Muscle Insulin Insensitivity
Yakar, S., Liu, J.-L., Fernandez, A. M., Wu, Y., Schally, A. V., Frystyk, J., Chernausek, S. D., Mejia, W., & Le Roith, D. (2001) · Diabetes · doi:10.2337/diabetes.50.5.1110 · Cited by 343
Frystyk, J. (2004) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2004.06.001 · Cited by 338
Metabolic Actions of Insulin-Like Growth Factor-I in Normal Physiology and Diabetes
Clemmons, D. R. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.04.017 · Cited by 297
Self-citationInsulin-like growth factor-1 deficiency and metabolic syndrome
Aguirre, G. A., De Ita, J. R., de la Garza, R. G., & Castilla-Cortazar, I. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-015-0762-z · Cited by 295
Human conditions of insulin-like growth factor-I (IGF-I) deficiency
Puche, J. E., & Castilla-Cortázar, I. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-224 · Cited by 268
Smith, T. J. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002469 · Cited by 267
Insulin-Like Growth Factor-1 as a Vascular Protective Factor
Conti, E., Carrozza, C., Capoluongo, E., Volpe, M., Crea, F., Zuppi, C., & Andreotti, F. (2004) · Circulation · doi:10.1161/01.cir.0000144309.87183.fb · Cited by 253
The GH–IGF‐I axis and the cardiovascular system: clinical implications
Colao, A. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03292.x · Cited by 209
Pennisi, P., Gavrilova, O., Setser-Portas, J., Jou, W., Santopietro, S., Clemmons, D., Yakar, S., & LeRoith, D. (2006) · Endocrinology · doi:10.1210/en.2005-1556 · Cited by 51
Self-citationMasi, D., Risi, R., Biagi, F., Vasquez Barahona, D., Watanabe, M., Zilich, R., Gabrielli, G., Santin, P., Mariani, S., Lubrano, C., et al. (2022) · Nutrients · doi:10.3390/nu14020373 · Cited by 20
“Epidemiological studies have suggested that IGF-1 levels in the upper normal range are associated with increased insulin sensitivity, better liver status and reduced blood pressure [66–69].”
BackgroundManagement of severe insulin resistance in patients with type 1 diabetes
Schechter, R., & Reutrakul, S. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0641-2 · Cited by 15
Metadata
- Authors
- Clemmons, D. R., Moses, A. C., McKay, M. J., Sommer, A., Rosen, D. M., & Ruckle, J.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2000-04
- Volume
- 85
- Issue
- 4
- Pages
- 1518-1524
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1994256100
- Cited by
- 128
- References
- 2
- FWCI
- 7.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.